English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/182760
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms

AuthorsTorrens, Gabriel; Cabot, Gabriel; Ocampo-Sosa, Alain Antonio; Conejo, M. Carmen; Zamorano, Laura; Navarro, Ferrán; Pascual, Álvaro; Martínez-Martínez, Luis; Oliver, Antonio
Issue DateOct-2016
PublisherAmerican Society for Microbiology
CitationAntimicrobial Agents and Chemotherapy 60(10): 6407-6410 (2016)
AbstractThe activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at ≤4 μg/ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant β-lactam resistance mechanisms.
Publisher version (URL)https://doi.org/10.1128/AAC.01282-16
URIhttp://hdl.handle.net/10261/182760
DOI10.1128/AAC.01282-16
ISSN0066-4804
E-ISSN1098-6596
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.